Synovis Life Technologies (Nasdaq: SYNO) has received USFDA clearance for an additional indication for Veritas® Collagen Matrix, an implantable, biomedical material that provides a scaffold into which the body's own tissue can grow, thereby effectively remodeling the implant to the host tissue.

Veritas® minimizes internal tissue attachment, a common and painful post-surgical complication.

Veritas is a biological material derived from bovine pericardium (a sac-shaped tissue surrounding the heart), which exhibits great suppleness and durability. As it is being placed in the human body, it handles and conforms like the patient's own tissue facilitating the surgical procedure and enabling normal healing.

The USFDA has granted the additional indication following Synovis' completion of a research in 2006 that investigated the adhesion formation and the tenacity of adhesions post surgery, and demonstrated that Veritas implants had minimal tissue attachment.

In addition to Synovis' U.S. patent for the process to manufacture Veritas, the company has just been issued another U.S. patent for "a method and composition for preventing surgical adhesions."

According to Richard Kramp, president and chief executive officer of Synovis Life Technologies:

"Receiving this additional indication from the FDA for Veritas is significant news for Synovis, and supports our strategy to maximize the applications for Veritas in many areas of soft tissue repair."

Find more details from the press release.